Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Mulls Laws To Accredit Ethics Committees To Streamline Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

The government is looking to tighten laws that would make ethics committees more accountable

You may also be interested in...



Clinical Research Is Booming In India But Are There Enough IRBs?

MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel